NEW YORK, May 18, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has
Download full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that at the general meeting of the Company held today the resolution to cancel the share premium account of the Company and
Download full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that, following legal advice, it has taken the decision to remove the offering restrictions imposed by US securities law
Download full announcement Proposed capital reduction and notice of General Meeting Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that a circular (a “Circular”) will today be sent to
NEW YORK, April 27, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announced today that it has received ISO 13485:2016 certification for its development and commercial laboratory
NEW YORK, April 27, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announced today that it has received ISO 13485:2016 certification for its development and commercial laboratory
Download full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that the KidneyIntelX ™ platform will be used by investigators from the Icahn School of Medicine at Mount Sinai to
NEW YORK, April 20, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that the KidneyIntelX™ platform will be used by investigators from the Icahn School of Medicine
Download full announcement Agreement with Three Rivers Provider Network, the fastest growing US proprietary provider network KidneyIntelX risk assessment testing now available to Three Rivers members and clients Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial
Keyword Company EPIC/TIDM SEDOL/ISIN News Price Announcements Fundamentals News Article RSS Renalytix AI PLC (RENX) Add to Alerts list Print Mail a friend Wednesday 01 April, 2020 Renalytix AI PLC RNS Number : 3212I Renalytix AI PLC 01 April 2020 Renalytix AI plc